FDB and Translational Software Announce Collaboration to Deliver Pharmacogenomic Drug Knowledge
Joint Effort Will Provide Relevant and Actionable Genomic and Drug Interaction Decision Support within Clinical Workflows
February 06, 2017
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–FDB (First Databank, Inc.), the leading provider of clinical drug knowledge that improves medication-related decisions and patient outcomes, and Translational Software, Inc. (TSI), a leader in the intelligent use of genetic data for clinical decision support, today announced a collaboration to develop pharmacogenomics (PGx)-based drug knowledge within health information system workflows.
The new drug knowledge will combine FDB’s MedKnowledge™ content and TSI’s proprietary PGx knowledge base data with relevant genomic-based laboratory findings to help clinicians make informed medication decisions for effective patient treatment. Integrated within the existing clinical workflow, the drug knowledge will provide pre-emptive testing prompts, genomic decision support, and advanced drug-drug-gene interaction alerting.
Initial use cases will enable clinicians to consider the genomic profile of a patient when making prescribing decisions (such as recommendations for drug monitoring, dose adjustments or prescribe contraindicated); and to consider genomic-related risk information when two drugs are prescribed together. This functionality will help guide clinical decision making, minimize adverse reactions and enable physicians to prescribe the most effective medication in a manner that meets the unique needs of individual patients.